Silent Crohn’s disease' is a form of inflammatory bowel disease that may develop without typical or obvious symptoms.

Conference call will be held today, Tuesday, November 11 at 9:00 am ETCARMEL, Ind., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical ...

Currently, no FDA-approved drug therapies exist for pediatric patients with abdominal pain-related disorders of gut-brain interaction (DGBIs), a significant unmet medical need. In the absence of ...

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic ...

NeurAxis, Inc. (($NRXS)) has held its Q3 earnings call. Read on for the main highlights of the call. NeurAxis, Inc. recently held its earnings ...

Discover key insights from NeurAxis' Q3 2025 earnings call—revenue growth, commercialization strategy, and outlook ahead of the new CPT code in 2026.

Hartmann et al. use ultra-high field 7 T fMRI to investigate shared neurobiological mechanisms between Crohn’s disease (CD) and major depressive disorder (MDD). Their findings reveal overlapping ...